Join our daily newsletter At The Bell to receive exclusive market insights
- Pregnancy technology company HeraMED (HMD) has signed a pilot agreement with Obstetrix Medical Group
- Obstetrix is an affiliate of NYSE-listed Mednax which is one of the largest providers of women’s and children’s care in the United States
- The initial part of the agreement is for the purchase of 100 licences of HeraMED’s software and devices to determine the functionality and suitability
- Upon completion of the pilot agreement, Obstetrix and HeraMED will determine whether to enter a comprehensive agreement for wider deployment
- HeraCARE is an at-home digital pregnancy monitoring software-as-a-service platform designed to improve prenatal and postnatal care
- It does this by allowing mothers to become engaged in a collaborative process focussed on managing the social, medical and mental aspects of maternity
- HeraMED is down 3.03 per cent on the market and shares are trading at 16 cents
Pregnancy technology company HeraMED (HMD) has signed a pilot agreement with Obstetrix Medical Group.
Obstetrix is an affiliate of NYSE-listed Mednax, which is one of the largest providers of women’s and children’s care in the United States.
Its network spans over 2300 physicians in 39 U.S. states and Puerto Rico.
“We are looking forward to incorporating the HeraCARE platform into our health care management programs for pregnant women,” Maternal-Fetal Medicine Specialist at Obstetrix Santosh Pandipati said.
“The launch of this pilot program will determine the feasibility of implementing a new pregnancy care delivery ecosystem centred around pregnancy wellness and patient empowerment,” he added.
The initial part of the agreement is for the purchase of 100 licences of HeraMED’s software and devices to expectant mothers.
This will evaluate the functionality and suitability of the HeraCARE platform.
Upon completion of the pilot agreement, Obstetrix and HeraMED will determine whether to enter a comprehensive agreement for wider deployment.
HeraCARE is an at-home digital pregnancy monitoring software-as-a-service platform designed to improve prenatal and postnatal care.
It does this by allowing mothers to become engaged in a collaborative process focussed on managing the social, medical and mental aspects of maternity.
Expecting mothers can read articles and blogs with the most recent and accurate information surrounding pregnancy.
“We are delighted to have signed our first pilot agreement in the U.S. with a company of such significant status and scale,” HeraMED CEO and Co Founder David Groberman commented.
“As a physician-led national medical group that partners with hospitals, health systems and health care facilities, focused exclusively on women’s and children’s care, Obstetrix Medical Group is a highly relevant partner and very well placed to support our commercialisation strategy,” he added.
HeraMED is down 3.03 per cent on the market and shares are trading at 16 cents at 11:02 am AEST.
